Study of the Cleavage of the Egg in Relation to the Stimulation Treatment

Ferring Pharmaceuticals356 enrolled

Overview

This post-marketing, single-center prospective study will be conducted in an open-label, non-interventional setting, for women seeking fertility treatment and will describe cleavage dynamics in relation to the age of the oocyte and gonadotrophin treatment.

Study Type

OBSERVATIONAL

Enrollment

356

Conditions

Female Infertility

Eligibility

Sex: FEMALEMin age: 38 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. IVF/ICSI treatment 2. Regular cycles of 25-35 days 3. Follicle stimulation with Bravelle and/or Menopur 4. Women aged 38-35 years 5. Long agonist or short antagonist treatment 6. Willing and able to understand a Danish, English or German patient information form 7. Willing and able to provide written Informed Consent Exclusion Criteria: 1. BMI more than 35 2. Presence of hydrosalpinx on ultrasound 3. FSH more than 13 or antral follicle count (AFC) less than 4 at fertility investigation 4. Known allergic reactions to the planned medications 5. Use of testicular sperm

Locations (1)

Danish Fertility Clinic

Frederiksberg, Copenhagen, Denmark